Biovail Dismisses Inappropriate and Unnecessary Debate.Vote Your BLUE Proxy Now TORONTO -- Biovail Corporation (NYSE NYSE See: New York Stock Exchange : BVF BVF Biovail Corporation (stock symbol) BVF Berufsverband der Frauenärzte eV (Muenchen, Germany) BVF Bearing Versus Frequency ) (TSX TSX Toronto Stock Exchange (TSE before April, 2002) TSX Transfer from Stack Pointer to Index TSX True Space Extension : BVF) today said it will rely on shareholders' ability to consider the facts and will not participate in the latest desperate publicity stunt A publicity stunt is a planned event designed to attract the public's attention to the promoters or their causes. Publicity stunts can be professionally organised or set up by amateurs. Amateur stunts can be trivial or deathly serious. from Eugene Melnyk Eugene Melnyk (born May 27, 1959 in Toronto, Ontario) is a Canadian businessman of Ukrainian origin who now resides in Barbados. He is the chairman and chief executive officer of Biovail Corporation. in his attempt to gain control of the Company's Board of Directors. The staged "debate," as proposed by Mr. Melnyk, involving management, current and imagined, who would report to that Board, is not appropriate or helpful. Biovail believes the question of the future direction of the Company is a serious matter for all 56,000 shareholders and should be decided on the facts, not by three-minute "sound bites." Biovail has fully described the capabilities and independence of its Board nominees, as well as the Company's New Strategic Focus designed to create sustainable value Sustainable Value Sustainable Value is an approach to measure and manage sustainability performance. The concept was developed by researchers who are working today for Queen's University Belfast for shareholders. This information is readily available on Biovail's website at www.biovail.com or at www.sedar.com. [TABLE OMITTED] About Biovail Corporation Biovail Corporation is a specialty pharmaceutical company, engaged in the formulation, clinical testing, registration, manufacture, and commercialization of pharmaceutical products utilizing advanced drug-delivery technologies. For more information about Biovail, visit the Company's Web site at www.biovail.com. For further information, please contact Nelson F. Isabel at 905-286-3000 or send inquiries to ir@biovail.com. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion